Symptoms of Lower Urinary Tract Dysfunction Phenotyping Study



Status:Completed
Conditions:Other Indications
Therapuetic Areas:Other
Healthy:No
Age Range:18 - Any
Updated:1/17/2019
Start Date:April 2015
End Date:May 2018

Use our guide to learn which trials are right for you!

Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Phenotyping Study Protocol

The purpose of this study is to advance our understanding of people who experience urinary
and bladder problems. We are interested in learning about people's experiences with urinary
symptoms and how these symptoms will be managed. We want to understand the important
differences among people and what factors affect urinary and bladder problems. After all of
the information is collected, we will have a better understanding of how to improve the care
and treatment for people who have urinary and bladder problems.

The Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) was established by
the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to advance our
understanding of lower urinary tract dysfunction (LUTD) in women and men. LUTD is a term
intended to be comprehensive and to challenge current paradigms about how symptomatic pelvic
disorders are defined as 'diseases.' Lower urinary tract symptoms (LUTS) are likely caused
and exacerbated by a variety of factors and thus do not represent the manifestation of a
single disease. Clinical management of LUTD, including treatment outcomes, remains suboptimal
since the biological and psychosocial factors that initiate, exacerbate, and modify this
group of symptoms remain largely unknown. As an initial effort to better characterize the
biological and psychosocial factors that initiate, exacerbate, and modify LUTS, the LURN
investigators will establish a prospective Observational Cohort Study of men and women with
LUTS presenting for the first time to LURN physicians.

Information to be obtained from study participants initially (at time of enrollment) includes
a standardized clinical examination, medical history, select testing of the lower urinary
tract, and participants' self-report of LUTS, pelvic floor symptoms including sexual function
and bowel symptoms, depression, anxiety, sleep patterns, stress, metabolic risk factors, and
health-related quality of life. We will also collect serum, urine, saliva, and perineal swabs
from men and vaginal swabs from women for storage at the NIDDK Sample Repository for future
study by the LURN investigators and the broader research community. This information will be
used to construct subgroups of patients who have similar symptoms, clinical presentations,
comorbidities, pelvic floor dysfunctions, and psychological profiles. These patient
characteristics and behaviors likely affect the evaluation, diagnosis, and/or treatment of
LUTS. Additional information will be collected 3 months and 12 months after enrollment or 3
and 12 months after surgery for patients receiving surgical treatment, and will include an
interval clinical history, participants' self-report of LUTS, pelvic floor symptoms including
sexual function and bowel symptoms, depression, anxiety, and health-related quality of life.
We will also collect biological samples at 3 and 12 months after enrollment.

The LURN Neuroimaging and Sensory Testing component of the study will investigate abnormal
sensation of the lower urinary tract at the level of the organism. Subjects and controls will
have a one-time visit soon after their baseline visit, where they will undergo an fMRI scan
of their brain and multimodal quantitative sensory testing assessing perceptual responses to
physical stimuli (pain and sound).

The information to be collected from the prospective Observational Cohort Study will be
limited and not sufficient to fully understand the pathophysiology and biology of LUTS.
Therefore, the Observational Cohort Study will serve as the basis for further LURN studies.
The long-term goal of the LURN is to better characterize patients with LUTD in order to
advance future research on the pathophysiology of these

Inclusion Criteria:

1. Men and women presenting for new patient visits for evaluation or treatment of LUTS to
one of the LURN physicians.

2. Age ≥ 18 years.

3. The presence of any of the symptoms reported in Table 1, based on responses to the
LUTS Tool with a one month recall period.

4. The ability to give informed consent and complete self-reported questionnaires
electronically.

Table 1: LUTS Appropriate for Study Inclusion

- Daytime frequency

- Nocturia

- Urgency

- Incontinence/leakage (various types)

- Poor or absent sensation of bladder filling

- Slow/weak stream

- Splitting or spraying

- Intermittent stream/Double voiding

- Hesitancy

- Straining

- Dribbling at the end of flow

- Paruesis (shy bladder syndrome)

- Poor or absent sensation of urethra during void

- Feeling of incomplete emptying

- Post-micturition dribble (delayed)

- Abnormal bladder or urethral sensations

Exclusion Criteria:

1. Gross hematuria.

2. Significant neurologic disease or injury, including but not limited to: cerebral
vascular accident with residual defect, Alzheimer's dementia, Parkinson's disease,
traumatic brain injury, spinal cord injury, complicated spinal surgery, multiple
sclerosis.

3. Primary complaint is pelvic pain.

4. Diagnosis of interstitial cystitis, chronic prostatitis, or chronic orchialgia.

5. Pelvic or endoscopic GU surgery within the preceding 6 months (not including
diagnostic cystoscopy).

6. Current sexually transmitted infection. (deferral; subject can enroll after negative
culture)

7. Ongoing symptomatic urethral stricture.

8. History of lower urinary tract or pelvic malignancy.

9. Current chemotherapy or other cancer therapy.

10. Pelvic device or implant complication (e.g., sling or mesh complications).

11. Current functioning neurostimulator.

12. Botox injection to the bladder or pelvic structures within the preceding 12 months.

13. In men, prostate biopsy in the previous 3 months.

14. In women, pregnancy.

15. History of cystitis caused by tuberculosis, radiation therapy, or
Cytoxan/cyclophosphamide therapy.

16. Augmentation cystoplasty or cystectomy.

17. Presence of urinary tract fistula.

18. Current major psychiatric disorder or other psychiatric or medical issues that would
interfere with study participation (e.g., dementia, psychosis, etc.).

19. Inability to relay valid information, actively participate in the study, or provide
informed consent (includes uncontrolled psychiatric disease).

20. Difficulty reading or communicating in English.
We found this trial at
6
sites
101 Jessup Hall
Iowa City, Iowa 52242
(319) 335-3500
Principal Investigator: Karl J Kreder, MD, MBA
Phone: 319-356-2910
University of Iowa With just over 30,000 students, the University of Iowa is one of...
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
Durham, North Carolina 27710
(919) 684-8111
Principal Investigator: Cindy L Amundsen, MD
Phone: 919-401-1017
Duke University Younger than most other prestigious U.S. research universities, Duke University consistently ranks among...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Seattle, Washington 98104
(206) 543-2100
Principal Investigator: Claire Yang, MD
Phone: 206-598-3293
Univ of Washington Founded in 1861 by a private gift of 10 acres in what...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
Principal Investigator: Quentin Clemens, MD, FACS
Phone: 734-936-5754
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Brian T Helfand, MD, PhD
Phone: 312-695-7748
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Henry Lai, MD
Phone: 314-747-8950
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials